Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Dong M. Shin, Sreenivas Nannapaneni, Mihir R. Patel, Qiuying Shi, Yuan Liu, Zhengjia Chen, Amy Y. Chen, Mark W. El-Deiry, Jonathan J. Beitler, Conor E. Steuer, Steven M. Roser, Adam M. Klein, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri, Zhuo G. Chen, Nabil F. Saba

Clin Cancer Res (2020) 26 (22): 5860–5868.

https://doi.org/10.1158/1078-0432.CCR-20-2276

Published: 13 November 2020

View article titled, Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

Includes: Supplementary data

Journal Articles

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Dongsheng Wang, Guoqing Qian, Hongzheng Zhang, Kelly R. Magliocca, Sreenivas Nannapaneni, A.R.M. Ruhul Amin, Michael Rossi, Mihir Patel, Mark El-Deiry, J. Trad Wadsworth, Zhengjia Chen, Fadlo R. Khuri, Dong M. Shin, Nabil F. Saba, Zhuo G. Chen

Clin Cancer Res (2017) 23 (3): 677–686.

https://doi.org/10.1158/1078-0432.CCR-16-0558

Published: 31 January 2017

View article titled, HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

Includes: Supplementary data

Journal Articles

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer

Clin Cancer Res (2015) 21 (8): 1859–1868.

https://doi.org/10.1158/1078-0432.CCR-14-1998

Published: 14 April 2015

View article titled, A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC

Rathi N. Pillai, Seth A. Brodie, Gabriel L. Sica, You Shaojin, Ge Li, Dana C. Nickleach, Liu Yuan, Vijay A. Varma, Dacian Bonta, James G. Herman, Malcom V. Brock, Maria J.A. Ribeiro, Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri, Johann C. Brandes

Clin Cancer Res (2013) 19 (6): 1603–1611.

https://doi.org/10.1158/1078-0432.CCR-12-2995

Published: 14 March 2013

View article titled, CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC

Includes: Supplementary data

Journal Articles

Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

Clin Cancer Res (2013) 19 (5): 1244–1256.

https://doi.org/10.1158/1078-0432.CCR-12-3149

Published: 03 March 2013

View article titled, Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

Includes: Supplementary data

Journal Articles

Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Michelle A.T. Hildebrandt, Scott M. Lippman, Carol J. Etzel, Edward Kim, J. Jack Lee, Fadlo R. Khuri, Margaret R. Spitz, Reuben Lotan, Waun Ki Hong, Xifeng Wu

Clin Cancer Res (2012) 18 (13): 3705–3713.

https://doi.org/10.1158/1078-0432.CCR-11-3271

Published: 01 July 2012

View article titled, Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Includes: Supplementary data

Journal Articles

Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

Seung Hyun Oh, Quanri Jin, Edward S. Kim, Fadlo R. Khuri, Ho-Young Lee

Clin Cancer Res (2008) 14 (5): 1581–1589.

https://doi.org/10.1158/1078-0432.CCR-07-0952

Published: 03 March 2008

View article titled, Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

Journal Articles

Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia

Scott M. Lippman, J. Jack Lee, Jack W. Martin, Adel K. El-Naggar, Xiaochun Xu, Dong M. Shin, Margaret Thomas, Li Mao, Herbert A. Fritsche, Jr., Xian Zhou, Vassiliki Papadimitrakopoulou, Fadlo R. Khuri, Hai Tran, Gary L. Clayman, Walter N. Hittelman, Waun Ki Hong, Reuben Lotan

Clin Cancer Res (2006) 12 (10): 3109–3114.

https://doi.org/10.1158/1078-0432.CCR-05-2636

Published: 17 May 2006

View article titled, Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia

Journal Articles

Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells

Wei Zou, Ping Yue, Na Lin, Min He, Zhongmei Zhou, Sagal Lonial, Fadlo R. Khuri, Binghe Wang, Shi-Yong Sun

Clin Cancer Res (2006) 12 (1): 273–280.

https://doi.org/10.1158/1078-0432.CCR-05-0503

Published: 05 January 2006

View article titled, Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells

Journal Articles

Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model

Xin Zhang, Zhuo (Georgia) Chen, Mi Sun Choe, Yan Lin, Shi-Yong Sun, H. Samuel Wieand, Hyung Ju C. Shin, Amy Chen, Fadlo R. Khuri, Dong M. Shin

Clin Cancer Res (2005) 11 (17): 6261–6269.

https://doi.org/10.1158/1078-0432.CCR-04-2102

Published: 06 September 2005

View article titled, Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model

Journal Articles

New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I

André Rogatko, James S. Babb, Mourad Tighiouart, Fadlo R. Khuri, Gary Hudes

Clin Cancer Res (2005) 11 (15): 5342–5346.

https://doi.org/10.1158/1078-0432.CCR-05-0458

Published: 01 August 2005

View article titled, New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I

Journal Articles

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

Roland L. Chu, Dawn E. Post, Fadlo R. Khuri, Erwin G. Van Meir

Clin Cancer Res (2004) 10 (16): 5299–5312.

https://doi.org/10.1158/1078-0432.CCR-0349-03

Published: 24 August 2004

View article titled, Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

Journal Articles

Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer

Fadlo R. Khuri, Victor Cohen

Clin Cancer Res (2004) 10 (12): 4249s–4253s.

https://doi.org/10.1158/1078-0432.CCR-040019

Published: 15 June 2004

View article titled, Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer

Journal Articles

Novel Agents in the Treatment of Lung Cancer: Conference Summary Statement

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Raymond N. DuBois, David R. Gandara, Giuseppe Giaccone, Ramaswamy Govindan, Roy S. Herbst, Bruce E. Johnson, Fadlo R. Khuri, Roman Perez-Soler, Rafael Rosell, Eric K. Rowinsky, Alan B. Sandler, Giorgio V. Scagliotti, Joan H. Schiller, Geoffrey I. Shapiro, Mark A. Socinski, Carol S. Hart

Clin Cancer Res (2004) 10 (12): 4199s–4204s.

https://doi.org/10.1158/1078-0432.CCR-040021

Published: 15 June 2004

View article titled, Novel Agents in the Treatment of Lung Cancer: <subtitle>Conference Summary Statement</subtitle>

Journal Articles

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Clin Cancer Res (2004) 10 (9): 2968–2976.

https://doi.org/10.1158/1078-0432.CCR-03-0412

Published: 06 May 2004

View article titled, Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Journal Articles

Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer

Jean-Charles Soria, Chulso Moon, Bonnie L. Kemp, Diane D. Liu, Lei Feng, Ximing Tang, Yoon-Soo Chang, Li Mao, Fadlo R. Khuri

Clin Cancer Res (2003) 9 (5): 1785–1791.

Published: 01 May 2003

View article titled, Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer

Journal Articles

Induction of p53-regulated Genes and Tumor Regression in Lung Cancer Patients after Intratumoral Delivery of Adenoviral p53 (INGN 201) and Radiation Therapy

Clin Cancer Res (2003) 9 (1): 93–101.

Published: 01 January 2003

View article titled, Induction of p53-regulated Genes and Tumor Regression in Lung Cancer Patients after Intratumoral Delivery of Adenoviral p53 (INGN 201) and Radiation Therapy

Journal Articles

Clinical Significance of Insulin-like Growth Factor-binding Protein-3 Expression in Stage I Non-Small Cell Lung Cancer

Yoon Soo Chang, Koo Gong, Shihua Sun, Diane Liu, Adel K. El-Naggar, Fadlo R. Khuri, Waun Ki Hong, Ho-Young Lee

Clin Cancer Res (2002) 8 (12): 3796–3802.

Published: 01 December 2002

View article titled, Clinical Significance of Insulin-like Growth Factor-binding Protein-3 Expression in Stage I Non-Small Cell Lung Cancer

Journal Articles

Correlation between Insulin-like Growth Factor-binding Protein-3 Promoter Methylation and Prognosis of Patients with Stage I Non-Small Cell Lung Cancer

Yoon Soo Chang, Luo Wang, Diane Liu, Li Mao, Waun Ki Hong, Fadlo R. Khuri, Ho-Young Lee

Clin Cancer Res (2002) 8 (12): 3669–3675.

Published: 01 December 2002

View article titled, Correlation between Insulin-like Growth Factor-binding Protein-3 Promoter Methylation and Prognosis of Patients with Stage I Non-Small Cell Lung Cancer

Journal Articles

hTERT Expression Is a Prognostic Factor of Survival in Patients with Stage I Non-Small Cell Lung Cancer

Luo Wang, Jean-Charles Soria, Bonnie L. Kemp, Diane D. Liu, Li Mao, Fadlo R. Khuri

Clin Cancer Res (2002) 8 (9): 2883–2889.

Published: 01 September 2002

View article titled, hTERT Expression Is a Prognostic Factor of Survival in Patients with Stage I Non-Small Cell Lung Cancer

NARROW

Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer

CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC

Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies

Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention

Insulin-like Growth Factor-I Receptor Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in Survivin Expression

Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia

Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells

Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model

New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

Molecularly Targeted Approaches to the Chemoprevention of Lung Cancer

Novel Agents in the Treatment of Lung Cancer: Conference Summary Statement

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Lack of Interleukin-10 Expression Could Predict Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer

Induction of p53-regulated Genes and Tumor Regression in Lung Cancer Patients after Intratumoral Delivery of Adenoviral p53 (INGN 201) and Radiation Therapy

Clinical Significance of Insulin-like Growth Factor-binding Protein-3 Expression in Stage I Non-Small Cell Lung Cancer

Correlation between Insulin-like Growth Factor-binding Protein-3 Promoter Methylation and Prognosis of Patients with Stage I Non-Small Cell Lung Cancer

hTERT Expression Is a Prognostic Factor of Survival in Patients with Stage I Non-Small Cell Lung Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only